



ASX & Media Release

## \$4.29 Million Fully Underwritten Rights Issue

### Key highlights

- Fully underwritten, non-renounceable, one (1) for three (3) rights issue to raise approximately \$4.29 million before costs
- New shares priced at \$0.012, being a 18.4% discount to the 10 day VWAP
- One (1) listed option will be issued for every three (3) shares subscribed for and issued, exercisable at \$0.024 per option and expiring three (3) years from the date of issue.
- Rights Issue strongly supported by major Eligible Shareholders and Directors, sub-underwriting approximately \$850,000 of the Rights Issue.
- Gross proceeds will be utilised to support the development of PAT-DX1 as it progresses towards an anticipated clinical trial in late 2021 or early 2022, to fund broader development of the Deoxymab platform including nanoparticle conjugation (PAT-DX1-NP) and alternate formats of the technology, as well as funding operations, offer costs, working capital, and other business development and corporate activities.

**Melbourne, Australia; 22 June 2020:** Patrys Limited (ASX: PAB, “Patrys” or the **Company**), a therapeutic antibody development company, is pleased to announce a fully underwritten, non-renounceable rights issue on the basis of one (1) new fully paid ordinary share for every three (3) shares currently held (**Rights Issue**) to Eligible Shareholders (defined below) at an issue price of \$0.012 per share (**Issue Price**) to raise approximately \$4.29 million before costs.

Shareholders will also receive one (1) option for every three (3) shares subscribed for and issued, exercisable at \$0.024 per option with a term of three (3) years. These options are expected to be listed on the ASX.

Patrys is also offering Eligible Shareholders the right to increase their shareholding in the Company (**Share Top Up Facility**) should there be any shortfall under the Rights Issue.

The Rights Issue is fully underwritten by Lazarus Corporate Finance Pty Ltd (**Underwriter**).

Eligible Shareholders are those shareholders with a registered address within Australia or New Zealand as at 7.00 p.m. (AEDT) on 2 July 2020 (**Record Date**). Shareholders with a registered address outside Australia or New Zealand at the Record Date (**Excluded Shareholders**) will not be eligible to participate in either the Rights Issue or the Share Top Up Facility.

The Issue Price of \$0.012 per share is a 14.3% discount to the last closing price of \$0.014 per share on 17 June 2020 and a 18.4% discount to the 10 day volume weighted average price to 17 June 2020 of \$0.0147 per share.

The structure of the Rights Issue with a Share Top Up Facility has been designed to provide the maximum opportunity for existing Patrys shareholders to subscribe for further shares in the



Company, while at the same time ensuring that a sufficient amount of capital will be raised. The Directors believe a Rights Issue is the correct structure for this capital raising as it treats all shareholders equally and is non-dilutive to the extent that all Eligible Shareholders are given the opportunity to participate.

Patrys' largest two Eligible Shareholders have agreed to sub-underwrite the Rights Issue to approximately \$750,000. Similarly, entities associated with each of Patrys' Chairman, Mr John Read, and CEO, Dr James Campbell, have each committed \$50,000 of sub-underwriting, which is in excess of their respective Rights entitlements. Both Mr Read and Dr Campbell have waived any entitlement to receive fees from the Underwriter in respect of their sub-underwriting.

The proceeds raised pursuant to the Rights Issue and Share Top Up Facility will be used to support the development of PAT-DX1 as it progresses towards an anticipated clinical trial in late 2021 or early 2022. Proceeds will also be used to fund broader development of the Deoxymab platform including nanoparticle conjugation (PAT-DX1-NP) and alternate formats of the technology, as well as funding operations, the costs of the issue, working capital, and other business development and corporate activities.

The Rights Issue and Share Top Up Facility is being undertaken in accordance with section 713 of the Corporations Act 2001 (Cth) pursuant to a transaction specific prospectus (**Prospectus**) that will be issued on or about today which will contain further details on the Rights Issue.

The proposed timetable\* for the Rights Issue and Share Top Up Facility is as follows:

| <b>Event</b>  | <b>Date</b>   |
|---|---------------|
| Company announces Entitlement Offer and lodges Prospectus with ASX and ASIC                               | 22 June 2020  |
| Ex-date   | 1 July 2020   |
| Record Date for the Entitlement Offer   | 2 July 2020   |
| Dispatch of Prospectus and Entitlement and Acceptance Form to Eligible Shareholders via the Offer Website | 7 July 2020   |
| Entitlement Offer opens   | 7 July 2020   |
| Last day to extend the Closing Date of the Entitlement Offer  | 24 July 2020  |
| Entitlement Offer closes  | 29 July 2020  |
| Shares and New Options quoted on a deferred settlement basis  | 30 July 2020  |
| Announcement of Results of Entitlement Offer  | 3 August 2020 |
| Settlement of Entitlement Offer   | 5 August 2020 |
| Allotment of Shares and New Options under the Entitlement Offer   | 5 August 2020 |
| Normal trading of Shares and New Options issued under the Entitlement Offer expected to commence on ASX   | 6 August 2020 |
| Dispatch of holding statements  | 7 August 2020 |

\* Note: The timetable above is indicative only and may be subject to change without notice. The Company, with the consent of the Underwriters, reserves the right, subject to the Corporations Act, ASX Listing Rules and other applicable laws to amend or vary any or all of the dates and times without notice. In particular, the Company reserves the right to extend the closing date of the Entitlement Offer, accept late applications (either generally or in particular cases) and to withdraw the Entitlement Offer without prior notice.



The commencement of quotation of Shares and New Options is subject to confirmation from the ASX.

Full details of the Rights Issue and the Share Top Up Facility will be contained in the Prospectus available on the ASX and the Company's website.

The Entitlement Offer is available electronically only to Australian and New Zealand residents accessing and downloading or printing the electronic version of the Prospectus within Australia and New Zealand. Australian and New Zealand residents may view the Prospectus online at the Offer Website: [patrysoffer-ri.online.computershare.com](http://patrysoffer-ri.online.computershare.com).

**-Ends-**

This announcement is authorised for release by the Board of Directors of Patrys Limited.

**For further information, please contact:**

**General enquiries**

James Campbell  
Chief Executive Officer  
P: +61 3 96703273  
[info@patrys.com](mailto:info@patrys.com)

**Media enquiries:**

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

**Registered Office Address**

Level 4, 100 Albert Road  
South Melbourne VIC 3205

**About Patrys Limited**

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its Deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. More information can be found at [www.patrys.com](http://www.patrys.com).

**About Patrys' Deoxymab 3E10 platform – lead candidates PAT-DX1 and PAT-DX1-NP:**

Deoxymab 3E10 is a DNA damage-repair (DDR) antibody that was first identified in lupus as an autoantibody that bound to normal cells. Of particular interest is that whilst most antibodies bind to cell surface markers, Deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes and kills cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. Deoxymab 3E10 has single agent therapeutic potential and has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumors.

Patrys has developed a humanized form of Deoxymab 3E10, PAT-DX1 with improved activity over the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form (PAT-DX1-NP) towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants, xenograft and orthotopic models. Treatment with PAT-DX1 has been shown to



significantly improve survival in orthotopic models of both triple negative breast cancer brain metastases and glioblastoma. PAT-DX1 has also been shown to enhance the therapeutic effect of low dose radiation. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

Patrys' rights to Deoxymab 3E10 are part of a worldwide license to develop and commercialize as anti-cancer and diagnostic agents a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University.